Chemical Screen of TOR pathway GFP fusion proteins in S. cerevisiae

酿酒酵母 TOR 途径 GFP 融合蛋白的化学筛选

• 批准号: 7692448
• 负责人: MARGRET C. WERNER-WASHBURNE
• 金额: $ 2.5万
• 依托单位: UNIVERSITY OF NEW MEXICO
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-04-16 至 2011-04-15
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7692448
• 关键词: Adverse effects; Affect; Agonist; Antifungal Agents; Bacteria; Biological; Biological Assay; Cell Cycle; Cell Polarity; Cells; Chemicals; Chimeric Proteins; Collection; Complex; Cues; Cytostatics; Drug Industry; Flow Cytometry; Fluorescence; Growth; Immunosuppressive Agents; Island; Lactones; Libraries; Metabolism; Multiprotein Complexes; Organism; Pathway interactions; Pharmaceutical Preparations; Production; Protein Kinase; Proteins; Resistance; Saccharomyces cerevisiae; Saccharomycetales; Screening Result; Screening procedure; Sirolimus; Soil; Structure; Therapeutic; Yeasts; base; clinical application; cytotoxic; follow-up; fungus; inhibitor/antagonist; man; mutant; novel; protein expression; public health relevance; small molecule

DESCRIPTION (provided by applicant): We propose an HTS multiplex screening project to use small molecules to probe a complex, highly conserved, biological pathway. The project takes advantage of the yeast GFP strain collection to probe the TOR pathway, a pathway with therapeutic implications in man [1]. The target of rapamycin, TOR, is an essential ser/thr protein kinase that functions in two distinct multiprotein complexes, TOR complexes 1 and 2. The structure and functions of these complexes have been conserved from yeast to man. TOR complex 1 is inhibited by rapamycin and is thought to couple growth cues to cellular metabolism; TOR complex 2 is not inhibited by rapamycin and appears to regulate spatial aspects of growth, such as cell polarity [2, 3]. Rapamycin, an antifungal compound isolated from a bacterium found in soil on the island of Rapa Nui [4], was the drug originally used to characterize the TOR pathway in budding yeast (S. cerevisiae) by identifying mutants that were rapamycin sensitive or resistant [5]. Rapamycin acts as a cytostatic agent in fungi, arresting cells in a G0-like state. As a drug it is widely used as an immunosuppressant and rapamycin and derivatives of this macrocyclic lactone are being evaluated for a number of clinical applications. Because of its pleiotropic effects, rapamycin is thought of as a "dirty drug" in the pharmaceutical industry. To identify more specific TOR inhibitors and activators, we propose a cell-based multiplex high throughput flow cytometry assay to screen the MLSMR to define chemicals that target specific proteins in the TOR pathway. A chemical screen should yield small molecules that modulate specific branches of this pathway and these molecules may have significant therapeutic potential and fewer side effects. We will screen the yeast GFP-fusion strain set (4,159 strains) [6] prior to and post-rapamycin treatment in multiplex format because the fusion library is highly amenable to fluorescence-based flow cytometric readout. Change in fluorescence indicates that a chemical has affected production of the target GFP-fusion protein(s). Chemicals we identify that mimic or inhibit rapamycin activation will likely have targets in other organisms because TOR pathway components are highly conserved. We have already successfully screened this collection under two different growth conditions and have the capacity to identify chemicals affecting one or more than one of the multiplexed targets. We will conduct primary screens to detect both agonists and antagonists of the TOR pathway. As secondary screens, we will: 1) compare the impact of the novel molecules on protein expression in the GFP collection and 2) evaluate the ability of the small molecules to impact the cytostatic potential of rapamycin through analysis of cell cycle and/or growth arrest. Expected Results: The screen in the absence of rapamycin will reveal molecules that mimic rapamycin or otherwise impact the TOR pathway. The screen in the presence of rapamycin will reveal molecules that antagonize rapamycin. PUBLIC HEALTH RELEVANCE: We propose an HTS multiplex screening project to use small molecules to probe a complex, highly conserved, biological pathway. The project takes advantage of the yeast GFP strain collection to probe the TOR - target of rapamycin - pathway, a pathway with therapeutic implications in man.

描述（由申请人提供）：我们提出了一个HTS多重筛选项目，使用小分子来探测复杂的、高度保守的生物学途径。该项目利用酵母GFP菌株收集来探测TOR途径，这是一种在人类中具有治疗意义的途径[1]。雷帕霉素的靶标TOR是一种必需的ser/thr蛋白激酶，其在两种不同的多蛋白复合物TOR复合物1和2中起作用。这些复合物的结构和功能从酵母到人类都是保守的。TOR复合物1被雷帕霉素抑制，并被认为将生长因子与细胞代谢偶联; TOR复合物2不受雷帕霉素抑制，似乎调节生长的空间方面，如细胞极性[2，3]。雷帕霉素是一种从拉帕努伊岛土壤中发现的细菌中分离出来的抗真菌化合物[4]，最初是用于表征芽殖酵母中TOR途径的药物（S.通过鉴定雷帕霉素敏感性或抗性的突变体[5]。雷帕霉素在真菌中作为细胞生长抑制剂，将细胞阻滞在G 0样状态。作为一种药物，它被广泛用作免疫抑制剂，雷帕霉素和这种大环内酯的衍生物正在被评估用于许多临床应用。由于其多效性，雷帕霉素被认为是制药行业的“肮脏药物”。为了鉴定更特异性的TOR抑制剂和激活剂，我们提出了一种基于细胞的多重高通量流式细胞术分析来筛选MLSMR，以定义靶向TOR途径中特定蛋白质的化学物质。化学筛选应该产生调节该途径的特定分支的小分子，并且这些分子可能具有显著的治疗潜力和较少的副作用。我们将在雷帕霉素处理之前和之后以多重形式筛选酵母GFP融合菌株组（4，159株）[6]，因为融合文库非常适合基于荧光的流式细胞术读数。荧光的变化表明化学物质影响了目标GFP融合蛋白的产生。我们鉴定的模拟或抑制雷帕霉素活化的化学物质可能在其他生物体中具有靶点，因为TOR途径组分是高度保守的。我们已经在两种不同的生长条件下成功地筛选了这个集合，并有能力鉴定影响一个或多个多重靶标的化学物质。我们将进行初步筛选，以检测TOR通路的激动剂和拮抗剂。作为二次筛选，我们将：1）比较新分子对GFP集合中蛋白质表达的影响和2）通过分析细胞周期和/或生长停滞来评估小分子影响雷帕霉素的细胞抑制潜力的能力。预期结果：在不存在雷帕霉素的情况下的筛选将揭示模拟雷帕霉素或以其他方式影响TOR途径的分子。在雷帕霉素存在下的筛选将揭示拮抗雷帕霉素的分子。 公共卫生关系：我们提出了一个HTS多重筛选项目，使用小分子探测复杂的，高度保守的，生物途径。该项目利用酵母GFP菌株收集来探测雷帕霉素途径的TOR靶点，该途径在人类中具有治疗意义。